NEW YORK (GenomeWeb) – Myriad RBM said this week that it has signed a deal with Sanofi to measure cardiovascular risk biomarkers in subjects participating in the pharma firm's Phase III trial for its type II diabetes drug lixisenatide.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.